235 East 42nd Street
About Pfizer, Inc.
At Pfizer Worldwide Research & Development (WRD), Pfizer’s visionary discovery and development division and the largest research-based biomedical and pharmaceutical company in the world, we're not content waiting to witness the evolution of our industry. Instead, we’re driven by science, building on our current successes and capabilities, playing a critical role in developing critical medicines and treatments for patients around the world.
Pfizer’s OWNIT! Culture
Through Pfizer’s shared mission to impact global health, Pfizer has built a unique OWNIT! culture to empower you to play your part in each of Pfizer’s life-changing achievements. So what does OWNIT! mean? It means taking ownership of your career and the contribution you make to the business and the patients and customers impacted by Pfizer’s business. This encouragement for personal progress allows colleagues to treat each other with honesty and respect, to act quickly and decisively, all to deliver results with commitment and care.
Professional Development at Pfizer
Pfizer’s belief that every person matters is also what proves their commitment to you. Whatever your talent or skill, you will be taught how to become an expert in your field through tools like Pfizer’s Mentor Match online tool and creating detailed career “roadmaps” with your manager that take into account your interests and aspirations as well as Pfizer’s business needs. Managers are also encouraged to provide frequent performance feedback instead of relying solely on yearly evaluations. From here, you’ll be inspired to refine – and redefine – your personal and professional goals.
Diversity at Pfizer
Pfizer believes that diversity is just as crucial to building a successful business as it is to building a vibrant culture. Pfizer’s community is one of the greatest building aspects about their culture. And their Diversity and Inclusion team ensures that every colleague experiences a fair and supportive environment. From holding managers and leaders accountable for creating inclusive and equitable workplaces, to helping colleagues appreciate the value of diversity, Pfizer is a place where people from all backgrounds and abilities can build a fulfilling career and reach their full potential.
Finding Your Community and Making a Difference
With more than 95 Colleague Resource Groups (CRGs) located around the world, working at Pfizer means finding a community. Pfizer offers CRGs focused on the following groups: Asians, Blacks, colleagues with disabilities, Latinos, LGBTQ, Veterans and Women. These CRGs offer support, mentoring and networking opportunities to help members enhance their skills and advance their careers. They also help their communities by participating in volunteer and philanthropic activities, from sponsoring student scholarships to health fairs focused on the unique healthcare concerns of diverse populations.
Every day, Pfizer colleagues work across developed and emerging markets to advance wellness, prevention, treatments, and cures that challenge the most feared diseases of today. As one of the world’s premier pharmaceuticals companies, Pfizer’s network and influence spans the entire globe. But in every country and continent, Pfizer colleagues are energized by a unique spirit. No matter the role or responsibility, colleagues are empowered by the belief that the work they do has a direct impact on patients.
3913 articles with Pfizer, Inc.
According to the American Cancer Society, almost 601,000 people in the U.S. died of cancer in 2017. The two most common types of cancer are lung cancer and breast cancer, followed by colorectal cancer, prostate cancer and stomach cancer.
Pfizer Introduced Biosimilar RETACRIT™ (epoetin alfa-epbx) Injection in the U.S. at a Substantial Discount
RETACRIT to be Priced 57.1% Below the Wholesale Acquisition Cost (WAC) of Procrit® (epoetin alfa) and 33.5% Below the WAC of Epogen® (epoetin alfa)
Kymera Therapeutics secured $65 million in a Series B funding round that was supported, in part, by the investment arms of Pfizer and Sanofi.
Viagra and Cialis: PDE-5 Inhibitors May Have Broader Applications in Cancer, Neurology and Cardio...
11/13/2018Viagra (sildenafil), Pfizer’s blockbuster drug for erectile dysfunction, is a classic example of how a drug developed for one thing can turn out to be successful for another.
The pharma industry began to push back against the presidential blueprint for drug prices ahead of the election. Will that continue with a now divided Congress?
New Clinical Oncology Collaboration Between Nektar and Pfizer to Evaluate Combination of NKTR-214, a CD122-Biased Agonist, with Avelumab and Talazoparib or Enzalutamide in Multiple Cancers
Nektar Therapeutics announced that it has entered into an oncology clinical collaboration with Pfizer Inc. to evaluate several combination regimens in multiple cancer settings, including metastatic castration-resistant prostate cancer (mCRPC) and squamous cell carcinoma of the head and neck (SCCHN).
While many consider failure to be a completely negative experience, that’s not always the case, as every failure is still a lesson learned. Occasionally, these failures can even lead to some of the biggest breakthroughs in medical history.
Nektar Therapeutics, based in San Francisco, and New York-based Pfizer are teaming up to evaluate combination regimens in several cancer settings. Those include metastatic castration-resistant prostate cancer (mCRPC) and squamous cell carcinoma of the head and heck (SCCHN).
The U.S. FDA approved Pfizer’s Lorbrena (lorlatinib) for ALK-positive metastatic non-small cell lung cancer (NSCLC) in patients whose disease hasn’t progressed on crizotinib and at least one other ALK inhibitor or for patients whose disease has progressed on alectinib or ceritinib as the first AL...
11/5/2018Biopharma companies make key appointments to fill leadership positions. Let's take a look!
Pfizer Inc. (NYSE:PFE) today announced that the U.S. Food and Drug Administration (FDA) has approved LORBRENA® [lor-BREN-ah] (lorlatinib)
To suggest that the pharma industry is a reluctant partner in President Donald Trump’s attempts to decrease drug prices is to overstate the fact. But now the industry appears to be pushing back, at least a little bit.
Third-Quarter 2018 Revenues of $13.3 Billion, Reflecting 2% Operational Growth
Privately-held Grunenthal GmbH will pay AstraZeneca $700 million for the prescription medicine rights to acid-reflux medicine Nexium. The deal with AstraZeneca represents the largest investment in Grünenthal company history.
According to Jay Bradner, president of the Novartis Institutes for Biomedical Research, the company is cutting its drug programs from 430 to 340. One of the big areas the company is abandoning is infectious diseases. The decision is a result of a strategic review by Vasant (Vas) Narasimhan, the c...
Joint studies will evaluate one or more of Pfizer’s investigational NASH therapies in combination with Novartis’s FXR agonist for the treatment of the progressive liver disease
NASH is similar to cirrhosis of the liver but occurs in people that drink little or no alcohol. It is related to the obesity epidemic and affects at least three to five percent of the adult population worldwide. Many believe that combination therapies will be the best way to approach treating NAS...
10/29/2018Biopharma companies shore up leadership roles with new hires and appointments, at Axcella Health, Twist Bioscience, and more.
It has been six years since Johnson & Johnson first launched its JLABS incubators for the life science industry with a vision of providing assistance to startups that could potentially bring about a new paradigm of care for patients.
As part of a plan to lower prescription drug prices for millions of Americans, President Donald Trump is set to announce a sweeping plan to overhaul how Medicare pays for medication.